Immunocore (NASDAQ:IMCR) Rating Reiterated by Guggenheim

Immunocore (NASDAQ:IMCR)‘s stock had its “buy” rating reaffirmed by research analysts at Guggenheim in a report issued on Tuesday, Benzinga reports. They currently have a $92.00 price objective on the stock. Guggenheim’s price target suggests a potential upside of 57.35% from the stock’s current price.

Other research analysts have also issued reports about the company. Canaccord Genuity Group lifted their target price on Immunocore from $60.00 to $63.00 and gave the company a “hold” rating in a report on Thursday, February 29th. HC Wainwright reiterated a “buy” rating and issued a $90.00 target price on shares of Immunocore in a report on Wednesday, March 6th. Oppenheimer reiterated an “outperform” rating and issued a $87.00 target price (up from $85.00) on shares of Immunocore in a report on Thursday, February 29th. Mizuho lifted their target price on Immunocore from $86.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Finally, JPMorgan Chase & Co. raised their price target on Immunocore from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Two analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $81.50.

Immunocore Trading Up 2.0 %

Shares of Immunocore stock opened at $58.47 on Tuesday. Immunocore has a fifty-two week low of $42.21 and a fifty-two week high of $76.98. The stock has a 50 day moving average of $62.82 and a 200 day moving average of $60.59. The firm has a market capitalization of $2.91 billion, a price-to-earnings ratio of -50.40 and a beta of 0.89. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.77 and a current ratio of 3.80.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.12). The firm had revenue of $70.16 million for the quarter, compared to analysts’ expectations of $53.25 million. Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The company’s quarterly revenue was up 22.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.63) earnings per share. As a group, research analysts predict that Immunocore will post -1.54 earnings per share for the current year.

Institutional Trading of Immunocore

Hedge funds and other institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its position in shares of Immunocore by 103.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock worth $43,000 after purchasing an additional 426 shares in the last quarter. IFP Advisors Inc increased its position in Immunocore by 32.9% in the 3rd quarter. IFP Advisors Inc now owns 2,397 shares of the company’s stock valued at $124,000 after acquiring an additional 594 shares during the period. Exchange Traded Concepts LLC increased its position in Immunocore by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock valued at $181,000 after acquiring an additional 674 shares during the period. JGP Global Gestao de Recursos Ltda. acquired a new position in Immunocore in the 4th quarter valued at about $230,000. Finally, NEOS Investment Management LLC acquired a new position in Immunocore in the 4th quarter valued at about $262,000. Institutional investors and hedge funds own 84.50% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.